Skip to Content

J. Jack Lee, Ph.D., M.S., D.D.S.

Present Title & Affiliation

Primary Appointment

Professor of Biostatistics, Department of Biostatistics, Division of Quantitative Sciences, UTMDACC, Houston, TX

Dual/Joint/Adjunct Appointment

Adjunct Professor of Statistics, Rice University, Houston, TX
Adjunct Professor of Biostatistics, University of Texas School of Public Health, Houston, TX
Regular Member of the Graduate Faculty, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX

Research Interests

Dr. Lees areas of research interest include design and analysis of clinical trials, survival analysis, longitudinal data analysis, statistical computation/graphics, statistical methods for determining drug interaction in combination studies, and cancer chemoprevention. Dr. Lee has been working on the development and application of innovative Bayesian methods for cancer clinical trials. He also actively participates in many multidisciplinary translational research in head/neck and lung cancer teams funded by National Institute of Health (NIH) and the Department of Defense (DoD). He has particular interests in incorporating multiple biomarkers and adaptive designs to develop more efficient and ethical clinical trials.  

Dr. Lee is a Statistical Editor for the Journal of the National Cancer Institute and Cancer Prevention Research. He is a Fellow of the American Statistical Association.

Office Address

The University of Texas MD Anderson Cancer Center
1400 Pressler Street
Unit Number: 1411
Houston, TX 77030
Room Number: FCT4.6012
Phone: (713) 794-4158
Fax: (713) 563-4243

Education & Training

Degree-Granting Education

1989 UCLA, Los Angeles, CA, PHD, Biostatistics
1984 UCLA, Los Angeles, CA, MS, Biostatistics
1982 National Taiwan University, Taipei, Taiwan, DDS, Dentistry


Endowed Positions

John G. & Marie Stella Kenedy Foundation Chair in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009-present

Honors and Awards

2008 Fellow, American Statistical Association
2007 Margaret & James A. Elkins, Jr. Faculty Achievement Award in Cancer Prevention, UTMDACC
2006 Julie and Ben Rogers Award for Excellence in Prevention, Finalist
1998-1999 Stanley Schor Scholar, Merck Research Laboratories

Professional Memberships

American Association of Cancer Research
Member, 1998-present
American Society of Clinical Oncology
Member, 2003-present
American Society of Preventive Oncology
Member, 1995-2011
American Statistical Association
Member, 1984-present
Drug Information Association
Member, 2005-2007
International Association for the Study of Lung Cancer
Member, 2007-present
International Biometric Society
Member, 1990-present
International Chinese Statistical Association
Elected Member, Board of Directors, 2005-2007
Member, 1991-present
Society of Clinical Trials
Member, 1993-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Jain RK, Lee JJ, Hong D, Markman M, Gong J, Naing A, Wheler J, Kurzrock R. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse. Clin Cancer Res 16(4):1289-97, Feb 15, 2/2010. e-Pub 2/2010.
2. Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27(12):1976-82, 4/2009. e-Pub 3/2009. PMCID: PMC2738635.
3. Kajiwara Y, Panchabhai S, Liu DD, Kong M, Lee JJ, Levin VA. Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells. Technol Cancer Res Treat 8(2):163-76, 4/2009. PMID: 19334798.
4. Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, El-Naggar AK, Richards-Kortum R, Gillenwater AM. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer 115(8):1669-79, 4/2009. PMCID: PMC2728679.
5. William WN, Lin HY, Lee JJ, Lippman SM, Roth JA, Kim ES. Revisiting Stage IIIB and IV Non-small Cell Lung Cancer: Analysis of the Surveillance, Epidemiology, and End Results Data. Chest. e-Pub 3/24/2009. PMID: 19318668.
6. William WN, Lee JL, Shin DM, Hong WK, Liu S, Lee JJ, Lippman SM, Khuri FR, Kim ES. Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors. Am J Clin Oncol 32(1):15-9, 2/2009. PMID: 19194117.
7. Papadimitrakopoulou VA, Lee JJ, William WN, Martin JW, Thomas M, Kim ES, Khuri FR, Shin DM, Feng L, Hong WK, Lippman SM. Randomized Trial of 13-cis Retinoic Acid Compared With Retinyl Palmitate With or Without Beta-Carotene in Oral Premalignancy. J Clin Oncol 27(4):599-604, 2/2009. e-Pub 12/2008. PMCID: PMC2645856.
8. Papadimitrakopoulou V, Izzo JG, Liu DD, Myers J, Ceron TL, Lewin J, William WN, Atwell A, Lee JJ, Gillenwater A, El-Naggar A, Wu X, Lippman SM, Hittelman WN, Hong WK. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila Pa) 2(1):14-21, 1/2009. PMID: 19139013.
9. William WN, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA. High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila Pa) 2(1):22-6, 1/2009. PMID: 19139014.
10. Kim ES, Mauer AM, William WN, Tran HT, Liu D, Lee JJ, Windt P, Hong WK, Vokes EE, Herbst RS. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer. Cancer 115(8):1713-22, 2009. PMID: 19208430.
11. Pu X, Lippman SM, Yang H, Lee JJ, Wu X. Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer 115(7):1498-1506, 2009. PMCID: PMC2666299.
12. Moeller BJ, Rana V, Cannon BA, Williams MD, Sturgis EM, Ginsberg LE, Macapinlac HA, Lee JJ, Ang KK, Chao KS, Chronowski GM, Frank SJ, Morrison WH, Rosenthal DI, Weber RS, Garden AS, Lippman SM, Schwartz DL. Prospective Risk-Adjusted [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography Assessment of Radiation Response in Head and Neck Cancer. J Clin Oncol 27(15):2509-15, 2009. PMID: 19332725.
13. Ye Y, Lippman SM, Lee JJ, Chen M, Frazier ML, Spitz MR, Wu X. Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions. Cancer 113(9):2488-95, 11/2008. PMCID: PMC2577230.
14. Behrens C, Lin HY, Lee JJ, Raso MG, Hong WK, Wistuba II, Lotan R. Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer. Clin Cancer Res 14(19):6014-22, 10/2008. PMID: 18829480.
15. Kong M, Lee JJ. A semiparametric response surface model for assessing drug interaction. Biometrics 64(2):396-405, 6/2008. e-Pub 9/2007. PMID: 17900314.
16. Bhutani M, Pathak AK, Fan YH, Liu DD, Lee JJ, Tang H, Kurie JM, Morice RC, Kim ES, Hong WK, Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev Res (Phila) 1(1):39-44, 6/2008. PMID: 19138934.
17. Papadimitrakopoulou VA, William WN, Dannenberg AJ, Lippman SM, Lee JJ, Ondrey FG, Peterson DE, Feng L, Atwell A, El-Naggar AK, Nathan CA, Helman JI, Du B, Yueh B, Boyle JO. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14(7):2095-101, 4/2008. PMID: 18381950.
18. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26(3):354-60, 1/2008. PMID: 18202409.
19. Lee JJ, Liu DD. A predictive probability design for phase II cancer clinical trials. Clin Trials 5(2):93-106, 2008. PMID: 18375647.
20. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials 5(3):181-93, 2008. PMID: 18559407.
21. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: A quality of life-years analysis. Cancer 112(5):1058-1065, 2008. PMID: 18186497.
22. Yang H, Lippman SM, Huang M, Lee JJ, Wang W, Spitz MR, Wu X. Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. European Journal of Cancer 44(11):1603-1611, 2008.
23. Zhang L, Lee JJ, Tang H, Fan HT, Xiao L, Ren H, Kurie J, Morice RC, Hong WK, Mao L. Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prevention Res 1(2):112-8, 2008. PMID: 19138944.
24. Qu A, Lee JJ, Lindsay BG. Model diagnostic tests for selection informative correlation structure in correlated data. Biometrika 95(4):891-905, 2008.
25. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, Clayman GL, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. Clin Cancer Res 13(21):6532-9, 11/1/2007. PMID: 17975167.
26. Hittelman WN, Liu DD, Kurie JM, Lotan R, Lee JS, Khuri F, Ibarguen H, Morice RC, Walsh G, Roth JA, Minna J, Ro JY, Broxson A, Hong WK, Lee JJ. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst 99(21):1603-12, 11/2007. e-Pub 10/2007. PMID: 17971525.
27. Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FM. Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther 6(7):1962-72, 7/2007. PMID: 17620427.
28. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25(16):2164-70, 6/2007. PMID: 17538160.
29. Wang Y, Spitz MR, Lee JJ, Huang M, Lippman SM, Wu X. Nucleotide excision repair pathway genes and oral premalignant lesions. Clin Cancer Res 13(12):3753-8, 6/2007. PMID: 17575242.
30. Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol 25(15):1974-8, 5/2007. PMID: 17513803.
31. Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst 99(22):1668-82, 2007. PMID: 18000218.
32. Lee JJ, Kong M, Ayers GD, Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. J Biopharm Stat 17(3):461-80, 2007. PMID: 17479394.
33. Kong M, Lee JJ. A generalized response surface model with varying relative potency for assessing drug interaction. Biometrics 62(4):986-95, 12/2006. PMID: 17156272.
34. Lee JJ, Bekele BN, Zhou X, Cantor SB, Komaki R, Lee JS. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol 24(22):3597-603, 8/2006. PMID: 16877726.
35. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, Benner SE, Winn R, Pajak TF, Williams B, Shenouda G, Hodson I, Fu K, Shin DM, Vokes EE, Feng L, Goepfert H, Hong WK. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98(7):441-50, 4/2006. PMID: 16595780.
36. Lee JJ, Feng L. Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 23(19):4450-7, 7/2005. PMID: 15994154.
37. Moon H, Ahn H, Lee JJ, Kodell RL. A weighted-adjusted Peto's test when cause of death is not assigned. Environmental and Ecological Statistics 12(1):95-113, 3/2005. PMID: No PubMed.
38. Moon H, Ahn H, Kodell RL, Lee JJ. Estimation of k for the poly-k test with application to animal carcinogenicity studies. Stat Med 22:2619-36, 8/2003. PMID: 12898548.
39. Moon H, Lee JJ, Ahn H, Nikolova RG. Web-based simulator for sample size and power estimation in animal carcinogenesis studies. Journal of Statistical Software 7(13):1-36, 2002.
40. Lee JJ, Tseng C. Uniform power method for sample size calculation in historical control studies with binary response. Control Clin Trials 22:390-400, 8/2001. PMID: 11514040.
41. Lee JJ, Liu D, Lee JS, Kurie JM, Khuri FR, Ibarguen H, Morice RC, Walsh G, Ro JY, Broxson A, Hong WK, Hittelman WN. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst 93:1081-8, 7/2001. PMID: 11459869.
42. Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 93:605-18, 4/2001. PMID: 11309437.
43. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK, Lippman SM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 6:1702-10, 5/2000. PMID: 10815888.
44. Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. American Statistician 54:63-70, 2000.
45. Thall PF, Lee JJ, Tseng CH, Estey EH. Accrual strategies for phase I trials with delayed patient outcome. Stat Med 18:1155-69, 5/1999. PMID: 10363337.
46. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90:1514-28, 10/1998. PMID: 9790544.
47. Staniswalis JG, Lee JJ. Nonparametric regression analyses of longitudinal data. J Am Stat Assoc 93:1403-1418, 1998.
48. Lee JJ, Tu ZN. A Versatile One-Dimensional Distribution Plot: The BLiP Plot. American Statistician 51(4):353-8, 11/1997.
49. Lee JJ, Serachitopol DM, Brown BW. Likelihood weighted confidence intervals for the difference of two binomial proportions. Biom J 39:387-407, 1997.
50. Lee JJ, Trizna Z, Hsu TC, Spitz MR, Hong WK. A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. Cancer Epidemiol Biomarkers Prev 5:191-7, 3/1996. PMID: 8833619.
51. Lee JJ, Tu ZN. A better confidence interval for Kappa on measuring agreement between two raters with binary outcomes. Journal of Computational and Graphical Statistics 3:301-321, 1994.
52. Lee JJ, Li KC, Elashoff RM. On recensoring for censored paired data. J Am Stat Assoc 88:104-118, 1993.
53. Lee JJ. A note on the conditional approach to interval estimation in the calibration problem. Biometrics 47:1573-80, 12/1991. PMID: 1786330.
54. Elashoff RM, Lee JJ, Afifi AA. A note on confidence limits for quartiles with right censored data. Stat Med 8:1269-76, 10/1989. PMID: 2814074.
55. Afifi AA, Elashoff RM, Lee JJ. Simultaneous non-parametric confidence intervals for survival probabilities from censored data. Stat Med 5:653-62, 11/1986. PMID: 3823672.

Invited Articles

1. Lippman SM, Lee JJ. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66(6):2893-903, 3/2006. PMID: 16540634.
2. Lee JJ, Lieberman R, Sloan JA, Piantadosi S, Lippman SM. Design considerations for efficient prostate cancer chemoprevention trials. Urology 57(4 - Suppl 1):205-12, 4/2001. PMID: 11295629.
3. Leiberman, R, Nelson WG, Sakr WA, Meyskens FL, Klein EA, Wilding G, Partin AW, Lee JJ, Lippman SM. Executive summary of the National Cancer Institute Workshop: Highlights and recommendations. Urology 57(4 Suppl 1):4-27, 2001. PMID: 11295590.
4. Lee JJ. -carotene may not prevent second head and neck cancer. Commentary to Mayne ST et al. Cancer Res 61:1457-1463, 2001. Evidence-based Oncology 2:200-201, 2001.

Book Chapters

1. Lippman SM, Lee JJ. Cancer chemoprevention. In: The Molecular Basis of Cancer, 3rd. Ed(s) J Mendelsohn, PM Howley, MA Israel, JW Gray, CB Thompson. Saunders-Elsevier: Philadelphia, PA, 711-720, 2008.
2. Lee JJ. Clinical trial design for anticancer therapies. In: The Cancer Handbook, 2nd Ed. Ed(s) Alison M. Wiley: London, UK, 1330-44, 2007.
3. Lee JJ, Moon H. Calibration. In: Encyclopedia of Biostatistics. 1, 2nd Ed. Ed(s) P. Armitage and T. Colton. John Wiley & Sons Ltd. United Kingdom, 579-585, 2005.
4. Lee JJ. Design and Analysis of Clinical Trials. In: Cancer - Principles and Practice of Oncology Review. Ed(s) R. Govindan, 98-103, 2005.
5. Lee JJ. Statistical Methods of Biomarker Analysis for Head and Neck Carcinogenesis and Prevention. In: Head & Neck Cancers. Ed(s) JF Ensley, JS Gutkind, JR Jacobs and SM Lippman, 287-303, 2002.
6. Lee JJ. Calibration. In: Encyclopedia of Biostatistics. 1. Ed(s) P. Armitage and T. Colton. John Wiley & Sons Ltd. United Kingdom, 461-466, 1998.

Manuals, Teaching Aids, Other Teaching Publications

1. Lee JJ. Clinical Trials and Biometric Methodology. 15. ASCO Curriculum: Cancer Prevention, ASCO: Alexandria, VA, 1-30, 2007.

Grant & Contract Support

Title: Cancer Center Support Grant - Biostatistics Shared Resource (PPSR-21)
Funding Source: NIH/NCI
Role: Core Director
Principal Investigator: Ronald DePinho
Duration: 7/1/2013 - 6/30/2018
Title: Salivary gland tumor biorepository
Funding Source: NIH/NIDCR
Role: Biostatistician
Principal Investigator: Adel K. El-Naggar
Duration: 8/10/2009 - 8/9/2014
Title: MD Anderson Cancer Center Head and Neck SPORE, (PC-B)
Funding Source: NIH/NCI
Role: Core Director
Principal Investigator: Scott Lippman
Duration: 9/4/2008 - 7/31/2013
Title: PROSPECT, Profiling of resistance patterns & oncogenic signaling pathways in evaluation of cancers of the thorax and therapeutic target identification (PC-B)
Funding Source: Department of Defense (DOD)
Role: Core Director
Principal Investigator: Waun Hong
Duration: 6/1/2007 - 6/30/2012
Title: Molecular-Based Therapy for Oral Cancer Prevention, (PC-B)
Funding Source: NIH/NCI
Role: Core Leader
Principal Investigator: Scott Lippman
Duration: 8/1/2004 - 7/31/2012
Title: VITAL (Vanguard Trial Investigations of Therapeutic Approaches to Lung Cancer) - (PC-B)
Funding Source: Department of Defense (DOD)
Role: Core Director
Principal Investigator: Waun Hong
Duration: 12/15/2003 - 12/14/2009
Title: Phase I & II Clinical Trials of Chemopreventive Agents (PP-1)
Funding Source: NIH/NCI
Role: Biostatistician
Principal Investigator: Powel Brown
Duration: 9/30/2003 - 9/29/2012
Title: Fluorescence Spectroscopy to Detect Oral Neoplasia
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Ann Gillenwater
Duration: 4/1/2002 - 4/30/2014

Last updated: 8/23/2013